CANAQUEST MEDICAL CORP CANQFa clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system, announced statistically significant efficacy results from the dose and efficacy clinical study conducted by dr W. McIntyre BurnhamProfessor Emeritus of the Temerty Faculty of Medicine at the University of Toronto. Compared to standard CBD, CQ-001 (Cannabidiol “CBD” + IP Formula – Essential Fatty Acids) demonstrated 40% more seizure reduction at an intermediate dose in the maximal electroshock seizure model. This result shows that CQ-001 is stronger than standard CBD and could be used at a lower dose to achieve seizure control.

Highlights derived from the study are as follows:

• The improved efficacy from these clinical studies confirms the results of the pre-clinical studies obtained from dr Steven LavioletteProfessor and Neuroscientist, at Western University.

• These results set the stage for much lower dosages of CBD that will achieve the desired results without the negative side effects, and will define a clinical trial dosage of CQ-001 (Phase II/III, double-blind study, 60 patients).

• CanaQuest has identified the regulatory pathways to obtain Rx drug identification numbers for rare neurological epilepsy disorders in Canada and the US. It is estimated that CQ-001, combined with its proprietary processing and delivery method, will be approved in approximately 3 years.

“Further testing will be needed, but preliminary testing suggests that CQ-001 is more potent than regular CBD,” said Burnham, pharmacologist and co-director of EpLink.

Paul RamsayPresident, stated, “The clinical study results confirm the results of the pre-clinical study conducted at Western University and further reinforce the magnitude of this life-changing discovery.”

Get your daily dose of Cannabis News on Benzinga cannabis. Don’t miss important developments in the…